Handelsavisen
prelaunch
Companies ›Consumer Staples ›ELAB
EL
ELAB — Nasdaq Personal Care Products

PMGC Holdings Inc.

$1,08
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
LatestPMGC Holdings files 8-K on material agreement, triggering thesis revision
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
2,1M USD
P/E
—
EV / Rev
-4,1x
Div yield
—
Op margin
—
ROE
-61,5 %
Net margin
-1 313,0 %
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
2026-07-28
Ex-dividend
—
TR 1Y
—
About

PMGC Holdings Inc. is classified under Healthcare / Pharmaceuticals and appears not currently profitable on the latest normalized snapshot.

Business. PMGC Holdings Inc. (Nasdaq: ELAB) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm operates within the broader pharmaceuticals industry, focusing on product-based revenue generation. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data. The company is primarily listed on the Nasdaq stock exchange under the ticker symbol ELAB.

Classification85 %
SectorConsumer Staples
Industry groupPersonal Care Products
Generated · rules-based
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
  • EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
See all catalysts →

At a glance

Score→
16
composite score
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Morgan Stanley Smith Barney LLC
largest disclosed fund holder
Profitability→
-61,5 %
return on equity
Quality→
62
quality score (0-100)

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

1
  • MARKETSPMGC Holdings files 8-K on material agreement, triggering thesis revision2026-07-10

    • Sector rotation

    Sector1D1Mvs mkt
    Communication Services+2,2 %−5,5 %+1,3 %
    Materials+2,2 %+2,9 %+1,2 %
    Energy+0,8 %+5,9 %−0,1 %
    Health Care+0,7 %−1,3 %−0,2 %
    Real Estate+0,5 %+5,3 %−0,5 %
    Consumer Discretionary+0,3 %+9,4 %−0,6 %
    Information Technology+0,1 %+8,1 %−0,9 %
    Financials−0,4 %−2,7 %−1,4 %
    Consumer Staples · THIS SECTOR−0,5 %+3,1 %−1,4 %
    Industrials−1,0 %−0,3 %−2,0 %
    Utilities−1,9 %+28,2 %−2,8 %

    Developing storylines

    No tracked sagas currently linked to ELAB. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-07-14 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ2 2026 earnings (expected)2026-07-28 · estimated
    • Macro
    • Rate decisionBank of Canada rate decision (press conf.)2026-07-15 · CA
    • Rate decisionBank of Japan rate decision (press conf.)2026-07-16 · JP
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-07-16 · EU
    • Rate decisionFederal Reserve rate decision (press conf.)2026-07-29 · US
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · 2026-07-10

    Composite-score breakdown

    Score breakdown16
    Valuation+12
    Sentiment+15
    Risk penalty−11
    Missing signals−1

    Synthesis

    Business

    PMGC Holdings Inc. (Nasdaq: ELAB) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm operates within the broader pharmaceuticals industry, focusing on product-based revenue generation. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data. The company is primarily listed on the Nasdaq stock exchange under the ticker symbol ELAB.

    Classification85 %
    SectorConsumer Staples
    Industry groupPersonal Care Products
    AI synthesis
    GENERATED

    PMGC Holdings Inc. (ELAB) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.78 (rule-based classification). Capital structure on the latest snapshot: total assets 26,033,318 USD, total equity 12,606,453, short-term debt 0, long-term debt 0. Net cash position is approximately 4,717,858 USD. Self-calculated market cap is 2,304,757 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 681,994, gross profit 230,474, operating income 0, net income -4,967,259. Return on equity ~-61.5%. Return on assets ~-29.8%. Operating-cash-flow to net-income ratio is 0.77. Risk profile from automated assessment: liquidity risk high, dilution risk medium. Flags: Filings reference going-concern or substantial-doubt language.; Source documents mention dilution or offering risk.. Recent news context: [TRIGGER] 8-K: 8-K (sec_8k_material) on ELAB — filing_type=8-K; max_severity=high; ignored_items=['9.01']; material_items=['1.01']; all_items_found=['1.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001213900-26-076709). Additional context: 8-K: filing_type=8-K; max_severity=high; ignored_items=['9.01']; material_items=['1.01']; all_items_found=['1.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material.

    Key takeaways
    • Return on equity is about -61.5%.
    • Debt to equity is about 0.0x.
    • [TRIGGER] 8-K: 8-K (sec_8k_material) on ELAB — filing_type=8-K; max_severity=high; ignored_items=['9.01']; material_items=['1.01']; all_items_found=['1.01', '9.01']; severity_per_code={'1.01': 'high'}; contributing_watchers=sec_8k_material (source=sec_8k_material; url=0001213900-26-076709)
    • Companyfacts coverage was partial; recent filing facts backfilled cash_and_equivalents.
    • Forward-looking statements in this Quarterly Report may include, but are not limited to, statements and/or information related to: our financial performance and projections; our business prospects and opportunities; our business strategy and future operations; the projection of timing and delivery of products in the future; projected costs; expected production capacity; expectations regarding demand and acceptance of our products; estimated costs of research and development to develop new pipeline products; trends in the market in which we operate; the plans and objectives of management; our liquidity and capital requirements, including cash flows and uses of cash; trends relating to our industry; and plans relating to our current products.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights

    Revenue $682.0k; Net margin -728.3%.

    Revenue$682.0k
    Operating income—
    Net income-$5.0M
    Free cash flow-$3.3M
    EPS—
    Operating cash flow-$3.0M
    Financials
    Income statement
    Revenue$682.0k
    Gross profit$230.5k
    Operating income—
    Net income-$5.0M
    Margins
    Gross margin33.8%
    Operating margin—
    Net margin-728.3%
    FCF margin-490.1%
    Balance sheet
    Total assets$26.0M
    Total liabilities$13.4M
    Total equity$12.6M
    Cash & equivalents—
    Long-term debt—
    Cash flow
    Operating cash flow-$3.0M
    CapEx$363.1k
    Free cash flow-$3.3M
    SBC$8.2k
    Highlights
    • ▍Revenue $682.0k
    • ▍Net margin -728.3%

    Valuation FY

    Market price
    $1,08
    Market cap
    $2.3M
    Enterprise valueⓘ
    -$2.4M
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    -4.1x
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    0.3x
    P / Tangible bookⓘ
    0.3x
    Tangible book
    $6.9M
    Net cashⓘ
    $4.7M
    Current ratioⓘ
    1.4
    Debt / equityⓘ
    —
    ROAⓘ
    -29.8%
    ROEⓘ
    -61.5%
    Cash conversionⓘ
    77.0%
    CapEx / revenueⓘ
    75.0%
    SBC / revenueⓘ
    -3.2%
    Dilution ratioⓘ
    —

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskMedium
    Liquidity riskHigh
    Filing-based flags
    • Filings reference going-concern or substantial-doubt language.
    • Source documents mention dilution or offering risk.

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 1 125 692 sh5 grants5 insiders
    • Braeden LichtiDirector · Options → Common StockAcquired 450 277 @ $1,77grant · 2026-06-01
    • Kovalyov GeorgeDirector · Options → Common StockAcquired 75 046 @ $1,77grant · 2026-06-01
    • Parry JeffreyDirector · Options → Common StockAcquired 75 046 @ $1,77grant · 2026-06-01
    • Bensler GraydonDirector, Chief Executive Officer · Options → Common StockAcquired 450 277 @ $1,77grant · 2026-06-01
    • Daley JulianaDirector · Options → Common StockAcquired 75 046 @ $1,77grant · 2026-06-01

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Regulatory filings
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    • Reference data
    How metrics are computed
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Ev To Revenue
      enterprise_value / revenue
    • Market Cap
      market_price * shares_outstanding_diluted
    • Return On Assets
      net_income / total_assets
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Enterprise Value
      market_cap - net_cash
    Source documents
    • PMGC Holdings Inc. company facts · 2026-07-10
    • PMGC Holdings Inc. 10-Q 2026-05-15 · 2026-07-10
    • PMGC Holdings Inc. 10-K 2026-03-30 · 2026-07-10
    • PMGC Holdings Inc. 10-Q 2025-11-14 · 2026-07-10
    • PMGC Holdings Inc. 10-Q 2025-08-13 · 2026-07-10
    • 8-K (sec_8k_material) on ELAB · 2026-07-10

    Ownership & reference

    Top holders

    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    — missing data

    Short positioning

    331.1Kshares short-44.9% vs prior
    1days to cover
    53.1%short of daily vol
    132.9Kfails-to-deliver
    as of 2026-06-30 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ELABCanonical
    Nasdaq · USD

    Intel & risk

    What changed

    no material change vs prior analysis (walked 17 fields; 4 schema-expansion field(s) excluded)

    • Narrative— → —medium
    • Business summary— → —medium
    • Conclusion— → —medium
    • Key takeaways— → —medium
    • Company share pct— → —medium
    vs prior analysis 1 day ago
    peak dispatch · 2026-07-10
    OSINT findings
    Dilution riskMedium
    Liquidity riskHigh
    Filings reference going-concern or substantial-doubt language.
    Source documents mention dilution or offering risk.

    Evidence & claims

    From filings & derived data
    • R&D expense (annual): USD 147.01KUnknown
    • Total liabilities (annual): USD 5.03MUnknown
    • Current assets (annual): USD 6.87MUnknown
    • Pre-tax income (annual): USD -7.75MUnknown
    • Total operating expenses (annual): USD 7.07MUnknown
    • Revenue (annual): USD 590.08KUnknown
    • Shares outstanding (annual): 80.7KUnknown
    • Net income (annual): USD -7.75MUnknown
    • Cost of revenue (annual): USD 404.77KUnknown
    • Operating cash flow (annual): USD -5.93MUnknown
    • Gross profit (annual): USD 185.31KUnknown
    • Capex (annual): USD 442.25KUnknown
    • Shareholders' equity (annual): USD 7.84MUnknown
    • Current liabilities (annual): USD 3.94MUnknown
    • Total assets (annual): USD 12.87MUnknown
    • Operating cash flow (annual): USD -5.49MUnknown
    • Total liabilities (annual): USD 2.33MUnknown
    • Net income (annual): USD -6.25MUnknown
    • Current assets (annual): USD 6.05MUnknown
    • R&D expense (annual): USD 104.65KUnknown
    • Total operating expenses (annual): USD 3.66MUnknown
    • Cash & equivalents (annual): USD 3.98MUnknown
    • Total assets (annual): USD 8.99MUnknown
    • Capex (annual): USD 9.16KUnknown
    Showing 24 of 28 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-07-28EVENTUpcomingQ2 2026 earnings (expected) estimated date
    2026-07-10 04:37 UTCFILINGMaterial 8-K
    2026-07-08 04:39 UTCFILINGMaterial 8-K
    2026-06-08FILINGCURRENT REPORT →
    2026-06-05FILINGCURRENT REPORT →
    2026-06-01 00:00 UTCINSIDER5 insider transactions — 2026-06 5 derivative
    2026-06-01INSIDERDaley Juliana acquired 75.0k sh Options — Director
    2026-06-01INSIDERParry Jeffrey acquired 75.0k sh Options — Director
    2026-06-01INSIDERBensler Graydon acquired 450.3k sh Options — Director, Chief Executive Officer
    2026-06-01INSIDERBraeden Lichti acquired 450.3k sh Options — Director
    2026-06-01INSIDERKovalyov George acquired 75.0k sh Options — Director
    2026-05-15FILINGQUARTERLY REPORT →
    2026-05-13FILINGCURRENT REPORT →
    2026-04-28FILINGCURRENT REPORT →
    2026-04-23FILINGCURRENT REPORT →
    2026-04-21FILINGCURRENT REPORT →
    2026-04-17FILINGCURRENT REPORT →
    2026-04-09FILINGCURRENT REPORT →
    2026-04-08FILINGCURRENT REPORT →
    2026-03-31EARNINGSQuarterly results — Q4 2025 Revenue USD 0.7M · Net USD -5.0M
    2025-12-31EARNINGSQuarterly results — Q3 2025
    2025-12-31EARNINGSAnnual results — FY 2025 Revenue USD 0.6M · Net USD -7.7M
    2025-09-30EARNINGSQuarterly results — Q2 2025 Revenue USD 0.3M · Net USD -4.8M
    2025-06-30EARNINGSQuarterly results — Q1 2025 Net USD -2.2M
    2025-03-26 00:00 UTCINSIDER2 insider transactions — 2025-03
    2024-12-31EARNINGSAnnual results — FY 2024 Net USD -6.2M
    2023-12-31EARNINGSAnnual results — FY 2023 Revenue USD 1.7M · Net USD -4.3M
    2023-12-28 00:00 UTCINSIDER1 insider transaction — 2023-12
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-07-14 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage